Phenoconversion in Thiopurine and Methotrexate Pharmacotherapy: A Systematic Framework for Integrating Germline Pharmacogenomics with Dynamic Phenotype Markers
Pharmaceutics · 03.11.2026 · 18 (11) · 1415
DOI: 10.3390/pharmaceutics18111415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.11.2026. Verfasst von Ayaan Borthakur und 1 weiteren Autor:innen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pharmacogenomics (PGx) has improved thiopurine and methotrexate (MTX) safety by identifying inherited variants in drug-metabolizing enzymes and transporters, including TPMT, NUDT15, and folate-pathway genes. Genotype-guided dosing is established for thiopurines, whereas MTX PGx evidence in immune-mediated disease remains weaker, without comparable consensus recommendations. Germline genotype alone cannot fully predict the expressed pharmacological phenotype, and phenoconversion—discordance between genotype-predicted and actual metabolic capacity—remains insufficiently addressed during inflammation, infection, hospitalization, and co-medication changes.
Methods
This systematic review was conducted using prespecified eligibility and evidence-appraisal criteria and reported in accordance with PRISMA 2020 guidelines.
Results
Thiopurines and MTX were selected as contrasting evidence cases. Thiopurines have established TPMT/NUDT15-guided starting doses, routine safety monitoring, and erythrocyte 6-TGN/6-MMP measurements. In contrast, MTX pharmacogenetic associations remain inconsistent in immune-mediated disease; erythrocyte polyglutamate thresholds lack standardization, and concentration-guided interventions are established primarily in high-dose oncology. Across 45 core reports, the most reproducible dynamic modifiers included inflammation-mediated ADME suppression, drug–drug interactions, organ dysfunction, and exposure changes detectable through serial laboratory or metabolite measurements. Epigenetic, translational, post-translational, and microbiome mechanisms remain less clinically established. The operational thiopurine panel is therefore limited to TPMT/NUDT15 status, treatment context, CBC, liver/renal chemistry, disease-activity markers as reassessment triggers, and erythrocyte metabolites; DNA-TG and TPMT-locus methylation remain investigational.
Conclusions
The Phenotype-Predictive Score is a theoretical, hypothesis-generating framework, not a validated clinical score, calculator, or dosing algorithm. Its equations and module weights require future drug-, indication-, endpoint-, and time-horizon-specific estimation in multicenter cohorts using penalized regression or dynamic pharmacokinetic models. PPS must not reassign TPMT/NUDT15 metabolizer phenotypes or guide treatment until external validation establishes calibration, transportability, safety, and clinical net benefit.
Zitieren
APA
Borthakur, A., & Porrogi, P. (2026). Phenoconversion in Thiopurine and Methotrexate Pharmacotherapy: A Systematic Framework for Integrating Germline Pharmacogenomics with Dynamic Phenotype Markers. Pharmaceutics, 18(11), 1415. https://doi.org/10.3390/pharmaceutics18111415
Vancouver
Borthakur A, Porrogi P. Phenoconversion in Thiopurine and Methotrexate Pharmacotherapy: A Systematic Framework for Integrating Germline Pharmacogenomics with Dynamic Phenotype Markers. Pharmaceutics. 2026;18(11):1415. doi:10.3390/pharmaceutics18111415
BibTeX
@article{Borthakur2026,
author = {Borthakur, Ayaan and Porrogi, Pálma},
title = {Phenoconversion in Thiopurine and Methotrexate Pharmacotherapy: A Systematic Framework for Integrating Germline Pharmacogenomics with Dynamic Phenotype Markers},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1415},
doi = {10.3390/pharmaceutics18111415}
}
EUVIMED